Page last updated: 2024-10-15

2-met-4-(4-nitro)-phe-5-pronh2-enkephalin

Description

BW 942C: enkephalin-like pentapeptide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID145925536
MeSH IDM0132557

Synonyms (15)

Synonym
bw 942c
98311-64-9
tyr-met-o-gly-4-no2-phe-pro-nh2
2-met-4-(4-nitro)-phe-5-pronh2-enkephalin
bw-942-c
enkephalin, met(2)-4-nitro-phe(4)-pronh2(5)-
enkephalin, methionyl(2)-4-nitrophenylalanyl(4)-prolinamide(5)-
5tbz91wf5y ,
tyrosyl-methionyl-o-glycyl-para-nitro-phenylalanyl-prolinamide
l-prolinamide, l-tyrosyl-gamma-(methylsulfinyl)-d-alpha-aminobutyrylglycyl-4-nitro-l-phenylalanyl-, monoacetate (salt)
unii-5tbz91wf5y
l-prolinamide, l-tyrosyl-(2r)-2-amino-4-(methylsulfinyl)butanoylglycyl-4-nitro-l-phenylalanyl-, monoacetate (salt)
tyr-d-met(o)-gly-pno2-phe-pro-nh2 acetate salt
bw-942c acetate
AKOS040750952

Dosage Studied

ExcerptReference
" In Long-Evans rats, BW942C produced a biphasic dose-response curve for urine output with lower doses increasing and higher doses suppressing output."( Kappa opioid partial agonist activity of the enkephalin-like pentapeptide BW942C based on urination and in vitro studies in humans and animals.
Cone, EJ; Johnson, RE; Su, TP; Vaupel, DB, 1990
)
"025), bismuth subsalicylate (Pepto-Bismol) taken orally at a dosage of as low as 30 ml every half hour for eight doses was shown to be effective in reducing the frequently of episodes of diarrhea."( Nonantibiotic therapy for travelers' diarrhea.
DuPont, HL; Ericsson, CD; Johnson, PC,
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (88.89)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (40.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]